Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization

BACKGROUND: We previously reported a PI3K inhibitor S14161 which displays a promising preclinical activity against multiple myeloma (MM) and leukemia, but the chiral structure and poor solubility prevent its further application. METHODS: Six S14161 analogs were designed based on the structure–activi...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Kunkun, Xu, Xin, Chen, Guodong, Zeng, Yuanying, Zhu, Jingyu, Du, Xiaolin, Zhang, Zubin, Cao, Biyin, Liu, Zhaopeng, Mao, Xinliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924225/
https://www.ncbi.nlm.nih.gov/pubmed/24428908
http://dx.doi.org/10.1186/1756-8722-7-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924225/
https://www.ncbi.nlm.nih.gov/pubmed/24428908
http://dx.doi.org/10.1186/1756-8722-7-9

Ejemplares similares